Clinical Trials
225
Trial Phases
5 Phases
Drug Approvals
98
Drug Approvals
Loteprednol Etabonate Ophthalmic Suspension
- Product Name
- 露达舒
- Approval Number
- 国药准字HJ20160346
- Approval Date
- Nov 4, 2024
Loteprednol Etabonate Ophthalmic Suspension
- Product Name
- 露达舒
- Approval Number
- 国药准字HJ20160348
- Approval Date
- Nov 4, 2024
Loteprednol Etabonate Ophthalmic Suspension
- Product Name
- 露达舒
- Approval Number
- 国药准字HJ20160347
- Approval Date
- Nov 4, 2024
Loteprednol Etabonate and Tobramycin Eye Drops
- Product Name
- 氯替泼诺妥布霉素滴眼液
- Approval Number
- 国药准字HJ20160349
- Approval Date
- Oct 29, 2024
Loteprednol Etabonate and Tobramycin Eye Drops
- Product Name
- 氯替泼诺妥布霉素滴眼液
- Approval Number
- 国药准字HJ20160350
- Approval Date
- Oct 29, 2024
Loteprednol Etabonate Ophthalmic Suspension
- Product Name
- 氯替泼诺混悬滴眼液
- Approval Number
- 国药准字HJ20191002
- Approval Date
- May 11, 2023
Loteprednol Etabonate Ophthalmic Suspension
- Product Name
- 氯替泼诺混悬滴眼液
- Approval Number
- 国药准字HJ20180059
- Approval Date
- May 11, 2023
Loteprednol Etabonate and Tobramycin Eye Drops
- Product Name
- 氯替泼诺妥布霉素滴眼液
- Approval Number
- H20160350
- Approval Date
- Jun 19, 2020
Loteprednol Etabonate and Tobramycin Eye Drops
- Product Name
- 氯替泼诺妥布霉素滴眼液
- Approval Number
- H20160349
- Approval Date
- Jun 19, 2020
Loteprednol Etabonate Ophthalmic Suspension
- Product Name
- 露达舒
- Approval Number
- H20160347
- Approval Date
- Jun 11, 2020
- Prev
- 1
- 2
- Next
Clinical Trials
Distribution across different clinical trial phases (212 trials with phase data)• Click on a phase to view related trials
A Study to Evaluate Concomitant Perfluorohexyloctane Use With Contact Lens Wear
- Conditions
- Dry Eye
- Interventions
- Drug: Perfluorohexyloctane ophthalmic solution
- First Posted Date
- 2025-07-08
- Last Posted Date
- 2025-07-11
- Lead Sponsor
- Bausch & Lomb Incorporated
- Target Recruit Count
- 100
- Registration Number
- NCT07054606
- Locations
- 🇺🇸
Site 101, San Diego, California, United States
🇺🇸Site 105, San Francisco, California, United States
🇺🇸Site 107, Longwood, Florida, United States
A Study to Assess Safety, Tolerability, and Pharmacokinetics of Ascending Concentrations of Topical Ocular BL1332 in Healthy Volunteers
- Conditions
- Ocular Pain
- Interventions
- Drug: BL1332 ophthalmic solutionDrug: BL1332 ophthalmic vehicle
- First Posted Date
- 2025-05-18
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Bausch & Lomb Incorporated
- Target Recruit Count
- 24
- Registration Number
- NCT06978244
- Locations
- 🇺🇸
Site 101, Fair Lawn, New Jersey, United States
A Study Comparing the Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution 0.025% With Sodium Hyaluronate Relative to Lumify in Adult Subjects With Ocular Redness
- Conditions
- Ocular Redness
- Interventions
- Drug: BTOS-HADrug: Lumify®
- First Posted Date
- 2025-01-31
- Last Posted Date
- 2025-07-09
- Lead Sponsor
- Bausch & Lomb Incorporated
- Target Recruit Count
- 578
- Registration Number
- NCT06803654
- Locations
- 🇺🇸
Site 111, Northbrook, Illinois, United States
🇺🇸Site 109, Pittsburg, Kansas, United States
🇺🇸Site 106, Louisville, Kentucky, United States
Revive Toric RWE Study
- Conditions
- Astigmatism
- First Posted Date
- 2025-01-21
- Last Posted Date
- 2025-06-05
- Lead Sponsor
- Bausch & Lomb Incorporated
- Target Recruit Count
- 30
- Registration Number
- NCT06785194
- Locations
- 🇺🇸
Site 101, Orange Park, Florida, United States
🇺🇸Site 102, Orange Park, Florida, United States
🇺🇸Site 103, Canton, Georgia, United States
Effectiveness and Safety of the TENEO 317 Model 2 Excimer Laser to Treat Myopia With or Without Astigmatism by Transepithelial Photorefractive Keratectomy
- Conditions
- Myopia
- First Posted Date
- 2024-10-01
- Last Posted Date
- 2025-06-15
- Lead Sponsor
- Bausch & Lomb Incorporated
- Target Recruit Count
- 140
- Registration Number
- NCT06618547
- Prev
- 1
- 2
- 3
- 4
- 5
- 44
- Next
News
Lifitegrast Shows Long-Term Safety and Efficacy for Dry Eye Disease in 7-Year Analysis
A 7-year postmarketing analysis of lifitegrast ophthalmic solution 5% (Xiidra) confirms its favorable safety profile with no new safety signals identified across nearly 800,000 patient treatment years.
MIEBO Demonstrates Efficacy in Dry Eye Disease Treatment
MIEBO (perfluorohexyloctane ophthalmic solution) is FDA-approved for treating the signs and symptoms of dry eye disease (DED).